Clinical Trial Update: Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating low-dose interleukin-2 as an immunomodulatory treatment for early Alzheimer's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Centre Hospitalier St Anne | Conditions: Alzheimer Disease | Phase 2 | Status: RECRUITING